VANCOUVER, B.C., April 29, 2026 — ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to provide an update on recent advances within its in vivo CAR and therapeutic mRNA research and development programs.
ME Therapeutics continues to advance its in vivo chimeric antigen receptor (CAR) pipeline. The lead candidate is a dual CD19/CD22-targeted CAR that combines the recently licensed CD22 nanobody asset with a clinically tested CD19 construct. The CAR mRNAs are continuing to be optimized for expression and function in both T cells and myeloid cells. In parallel, ME Therapeutics is testing lipid nanoparticle (LNP) formulations engineered for effective in vivo mRNA delivery to human T cells and macrophages. Following optimization of the CAR mRNAs, ME Therapeutics will develop the lead CAR into specific LNP formulations for testing in humanized mouse cancer models. The CD19/CD22 dual CAR program aims to target certain forms of leukemia, lymphoma and autoimmune disease indications.
Preclinical testing is also progressing for ME Therapeutics’ lead therapeutic mRNA candidate targeting the STING (Stimulator of Interferon Genes) pathway. Recent data demonstrate dose-dependent single agent efficacy of the candidate in a mouse colorectal cancer model. Two modified versions of the candidate have been optimized to enhance expression of STING in the tumour microenvironment to potentially further increase their safety and will now move forward for further testing. The STING program aims to target solid tumours such as certain forms of colorectal cancer that are currently underserved by other immuno-oncology drugs.
“We are excited by the latest preclinical progress and momentum behind our in vivo CAR and therapeutic mRNA programs, which both hold the promise of offering novel approaches for cancer patients who today have few treatment options,” said Salim Dhanji, PhD, CEO of ME Therapeutics. “Our in vivo CD19/CD22-targeted CAR candidate has a potentially differentiated approach from the competition. Meanwhile, our therapeutic mRNA candidate targets STING, which is an important, highly validated pathway in many solid tumours that has been notoriously difficult to target using past approaches.”
About ME Therapeutics
Myeloid Enhancement (ME) Therapeutics is a publicly listed biotechnology company based in Vancouver focused on developing novel therapeutics designed to reprogramme immune cells in vivo to reshape the tumour microenvironment and to directly recognize and kill cancer cells. For more information, visit metherapeutics.com.
Contacts
Company: Salim Dhanji, PhD, salim@metherapeutics.com, +1-236-516-7714
Media: Claire Piech, claire@magneticcomms.com, +1-604-698-6637